# Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

> **NCT07035002** · PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)
- Tumor Infiltrating Lymphocytes
- PD-1

## Interventions

- **BIOLOGICAL:** transfusion of 5×10^8 PD-1 knockout TILs per kg body weight
- **BIOLOGICAL:** transfusion of 1×10^9 PD-1 edited TILs per kg body weight
- **BIOLOGICAL:** transfusion of 2×10^9 PD-1 edited TILs per kg body weight
- **BIOLOGICAL:** transfusion of maximum dose without side effects among group A, B and C

## Key facts

- **NCT ID:** NCT07035002
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07035002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07035002, "Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07035002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*